about
MO25 is a master regulator of SPAK/OSR1 and MST3/MST4/YSK1 protein kinasesStructural insights into the activation of MST3 by MO25SPAK/OSR1 regulate NKCC1 and WNK activity: analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation.Towards the Development of Small-Molecule MO25 Binders as Potential Indirect SPAK/OSR1 Kinase Inhibitors.Synthesis of pdCpAs and transfer RNAs activated with thiothreonine and derivatives.Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells.Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates.Organometallic nucleoside analogues with ferrocenyl linker groups: synthesis and cancer cell line studies.Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism.The design, synthesis and antiviral evaluation of a series of 5-trimethylsilyl-1-beta-D-(arabinofuranosyl)uracil phosphoramidate ProTides.The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction.BTN3A1 Discriminates γδ T Cell Phosphoantigens from Nonantigenic Small Molecules via a Conformational Sensor in Its B30.2 Domain.The ProTide Prodrug Technology: From the Concept to the Clinic.The ProTides Boom.Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial DepolarizationPhosphoramidate prodrugs deliver with potency against hepatitis C virus.An investigation into the anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U) and 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.The Anthelmintic Drug Niclosamide and its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1.WNK Signaling Inhibitors as Potential Antihypertensive Drugs.Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal Domains.Synthesis and Biological Evaluation of (E)-4-Hydroxy-3-Methylbut-2-enyl Phosphate (HMBP) Aryloxy Triester Phosphoramidate Prodrugs as Activators of Vγ9/Vδ2 T-Cells Immune Response.Niclosamide, a Drug with Many (Re)purposes.The Photosensitising Clinical Agent Verteporfin Is an Inhibitor of SPAK and OSR1 KinasesChemical Strategies for Activating PINK1, a Protein Kinase Mutated in Parkinson's DiseaseDesign, synthesis, and anti-HIV activity of 2′,3′-didehydro-2′,3′-dideoxyuridine (d4U), 2′,3′-dideoxyuridine (ddU) phosphoramidate ‘ProTide’ derivativesOrganometallic Nucleoside Analogues: Effect of Hydroxyalkyl Linker Length on Cancer Cell Line ToxicityAryloxy Triester Phosphoramidates as Phosphoserine Prodrugs: A Proof of Concept StudyThe Cul4-DDB1-WDR3/WDR6 Complex Binds SPAK and OSR1 Kinases in a Phosphorylation-Dependent MannerPhosphotyrosine prodrugs: design, synthesis and anti-STAT3 activity of ISS-610 aryloxy triester phosphoramidate prodrugs
P50
Q24297671-EA8C4C90-B1FF-4B05-BB1D-42939C816666Q27675802-BACFF547-5A13-4B7D-89FB-0A24C285AC47Q35623025-A273432F-C8EC-4517-BDBD-6935C12470DCQ36231073-93FF5EE4-CEE4-4E5E-9A03-410B9E3F5ADDQ36617647-FDF393F5-3559-4F14-A24D-9DA2B0504C8AQ37598750-C446AEB5-6946-43DB-B795-64572B3FF91AQ37604356-19B9A8A3-364D-4B2C-9F83-24DB2EE5B237Q38827975-5572526B-94EE-47C2-9A3B-558D336A2C5EQ38987612-270B796A-0469-4B77-9BF3-334AD534FB5DQ39726060-807893BF-40EA-41A0-A5D7-37D93DF93653Q39727337-B6078F48-675F-40B4-AC3D-919908AD1395Q39986392-4DAB44F5-1D57-4C98-A22D-2D7AC15620E3Q40070853-4702B973-3675-492A-87F4-9FC597DB1B1BQ40089234-2A747B73-138D-4247-B9BB-FC9F9F3FB076Q40682239-E836FDFE-9EA8-4224-9FA1-7934FF0017C9Q42290109-BB2C6E0F-5D4D-4705-80DA-B980D2FD7639Q42877580-8F79B832-3289-4731-A1A3-1DFDA5EF0436Q45979228-13589E07-11A6-4E34-A72B-B5FC13DE07E0Q47309289-578F2656-6197-454A-8494-517C0D9F6676Q47841545-3C24B7D9-A89E-4C50-8B20-BDB73A68B6E1Q48328507-33E4F530-5AE8-4BC9-BB53-1CC10087ED62Q49849833-85D47D8D-82B9-47E7-9F3A-ABF6C606166BQ54244503-3188BFEB-200D-48DE-A20F-744097EC12FCQ57025725-33A7F9E0-78D9-4CB9-BCC1-27E6921F0E74Q57151306-FACE09FE-82BD-4C88-AB88-2CC61BFFAF6CQ57266136-F0F076B7-74EE-4F70-ABE5-F539F654E401Q63976995-5714F6E0-8CDC-4DC9-8C0C-7603A264F127Q90257464-5A882493-790F-4975-A6E9-ABCF3A45D2DEQ90717955-F384AF09-3B2E-41F6-A69C-E7D3A1F23476Q92431295-E7AC99A0-2AA2-406B-9459-F8A5AB5F11AC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Youcef Mehellou
@ast
Youcef Mehellou
@en
Youcef Mehellou
@es
Youcef Mehellou
@nl
Youcef Mehellou
@sl
type
label
Youcef Mehellou
@ast
Youcef Mehellou
@en
Youcef Mehellou
@es
Youcef Mehellou
@nl
Youcef Mehellou
@sl
prefLabel
Youcef Mehellou
@ast
Youcef Mehellou
@en
Youcef Mehellou
@es
Youcef Mehellou
@nl
Youcef Mehellou
@sl
P106
P21
P31
P496
0000-0001-5720-8513
P569
2000-01-01T00:00:00Z